Evogene (Israel) Performance
| EVGN Stock | ILA 509.70 6.10 1.21% |
On a scale of 0 to 100, Evogene holds a performance score of 4. The firm shows a Beta (market volatility) of 0.15, which means not very significant fluctuations relative to the market. As returns on the market increase, Evogene's returns are expected to increase less than the market. However, during the bear market, the loss of holding Evogene is expected to be smaller as well. Please check Evogene's total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to make a quick decision on whether Evogene's price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Evogene are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Evogene sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 46.2 M | |
| Total Cashflows From Investing Activities | -20.6 M |
Evogene |
Evogene Relative Risk vs. Return Landscape
If you would invest 47,100 in Evogene on December 19, 2024 and sell it today you would earn a total of 3,260 from holding Evogene or generate 6.92% return on investment over 90 days. Evogene is generating 0.2279% of daily returns and assumes 4.449% volatility on return distribution over the 90 days horizon. Simply put, 39% of stocks are less volatile than Evogene, and 96% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Evogene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evogene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evogene, and traders can use it to determine the average amount a Evogene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0512
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EVGN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.45 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Evogene is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evogene by adding it to a well-diversified portfolio.
Evogene Fundamentals Growth
Evogene Stock prices reflect investors' perceptions of the future prospects and financial health of Evogene, and Evogene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evogene Stock performance.
| Return On Equity | -0.63 | |||
| Return On Asset | -0.28 | |||
| Operating Margin | (24.02) % | |||
| Current Valuation | 8.8 M | |||
| Shares Outstanding | 41.22 M | |||
| Price To Book | 0.93 X | |||
| Price To Sales | 73.01 X | |||
| Revenue | 930 K | |||
| EBITDA | (26.78 M) | |||
| Cash And Equivalents | 65.36 M | |||
| Cash Per Share | 1.61 X | |||
| Total Debt | 2.39 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.74 X | |||
| Cash Flow From Operations | (24.72 M) | |||
| Earnings Per Share | (0.72) X | |||
| Total Asset | 76.3 M | |||
| Retained Earnings | (90 M) | |||
| Current Asset | 95 M | |||
| Current Liabilities | 6 M | |||
About Evogene Performance
By analyzing Evogene's fundamental ratios, stakeholders can gain valuable insights into Evogene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Evogene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Evogene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. EVOGENE operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 131 people.Things to note about Evogene performance evaluation
Checking the ongoing alerts about Evogene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evogene help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evogene had very high historical volatility over the last 90 days | |
| The company reported the revenue of 930 K. Net Loss for the year was (27.79 M) with profit before overhead, payroll, taxes, and interest of 163 K. | |
| Evogene has accumulated about 65.36 M in cash with (24.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.61. |
- Analyzing Evogene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evogene's stock is overvalued or undervalued compared to its peers.
- Examining Evogene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evogene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evogene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evogene's stock. These opinions can provide insight into Evogene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Evogene Stock analysis
When running Evogene's price analysis, check to measure Evogene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evogene is operating at the current time. Most of Evogene's value examination focuses on studying past and present price action to predict the probability of Evogene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evogene's price. Additionally, you may evaluate how the addition of Evogene to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |